Core pipeline in development



The company holds patents.90Remaining items, with nearly … varieties under development.30Item, including projects that have entered the registration process.18item

Product Name
Preclinical
Phase I clinical trial
Phase II clinical trial
Phase III clinical trial
NDA
Quadrivalent Influenza Virus Split Vaccine (for individuals aged 3 years and older)
NDA
 
Adsorbed tetanus vaccine
NDA
 
Trivalent Influenza Virus Split Vaccine (for individuals aged 3 years and older)
NDA
 
Oral pentavalent reassortant live attenuated rotavirus vaccine (Vero cells)
Phase III clinical trial
 
Adsorbed Diphtheria–Tetanus–Pertussis (Component) Combined Vaccine (Infants and Young Children)
Phase I clinical trials have been completed, and the product is currently in Phase III clinical trials.
 
20-valent pneumococcal polysaccharide conjugate vaccine
Phase II clinical trial
 
Adsorbed acellular diphtheria–tetanus–pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine (pentavalent vaccine)
About to enter Phase III clinical trials.
 
Adsorbed Diphtheria–Tetanus–Pertussis Inactivated Poliovirus Combined Vaccine
Phase I clinical trial
 
Measles-Mumps-Rubella Combined Attenuated Live Vaccine
Phase I clinical trial
 
Quadrivalent Inactivated Enterovirus Vaccine (EV-A71/CV-A6/CV-A10/CV-A16) (Vero Cell)
Phase I clinical trial
 
Quadrivalent Influenza Virus Split Vaccine (for infants aged 6–35 months)
Approved for clinical trials
 
Quadrivalent Influenza Virus Split Vaccine (MDCK Cells)
Approved for clinical trials
 
24-valent pneumococcal polysaccharide conjugate vaccine
Preclinical
 
Combined attenuated live vaccine for measles, mumps, rubella, and varicella
Preclinical
 
Shingles vaccine
Preclinical
 
Respiratory Syncytial Virus Vaccine (RSV)
Preclinical
 
Combined vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
Preclinical
 
Klebsiella pneumoniae vaccine
Preclinical